E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Peripheral Artery Disease (PAD), Intermittent Claudication |
|
E.1.1.1 | Medical condition in easily understood language |
Peripheral artery disease, leg pain with exercise. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10022562 |
E.1.2 | Term | Intermittent claudication |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10034633 |
E.1.2 | Term | Peripheral vascular disease |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the safety and tolerability of LLG783 in patients with PAD and intermittent claudication after 16 weeks of exposure to LLG783
• To evaluate the effect of LLG783 on functional capacity after 3 months of treatment in patients with PAD and intermittent claudication. |
|
E.2.2 | Secondary objectives of the trial |
• To investigate the PK of LLG783 in patients with PAD and intermittent claudication.
• To evaluate the effect of LLG783 on symptomatic functional capacity after 3 months of treatment in patients with PAD and intermittent claudication
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Clinical evidence of PAD and intermittent claudication. Intermittent claudication, as defined by pain with exertion in either leg
• On stable medical therapy for PAD and PAD symptoms, which may include statins, aspirin, and antiplatelet medications (as medically indicated) unless individually contraindicated, for at least 4 weeks prior to the screening visit.
• Vital signs must be within the following ranges:
o body temperature between 35.0-37.5°C
o systolic blood pressure, 90-159 mm Hg
o diastolic blood pressure, 50-99 mm Hg
o pulse rate, 50 - 90 bpm
• Moderately impaired ambulatory function judged by the investigator to be due primarily to PAD and assessed by a maximum walk distance between 50 and 400 meters (inclusive of these values) at the screening 6MWT. |
|
E.4 | Principal exclusion criteria |
• Pregnant or nursing (lactating) women.
• Patients who meet any of the following PAD related criteria:
o Patients actively attending and participating in a supervised exercise rehabilitation program (patients who have already
completed such a program and remain symptomatic may be included).
o Patients with any condition other than PAD that limits walking
ability.
o Known inflammatory disease of the arteries (other than atherosclerosis; e.g. Thromboangiitis obliterans).
o Clinical evidence of critical limb ischemia including new or non-healing ulcers (felt secondary to critical limb ischemia), new or
recent onset of resting pain in the lower extremities particularly at
night (felt secondary to critical limb ischemia) and/or gangrene of
the lower extremities (Fontaine stage III-IV) .
• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 150 days after stopping of investigational drug
• Any of the following concomitant cardiovascular or metabolic conditions or diseases:
o Myocardial infarction within 6 months of screening.
o Stroke within 6 months of screening.
o History of clinically significant ventricular arrhythmias, according to
the discretion of the investigator, within 6 months of screening.
o Significant ECG abnormalities, according to the discretion of the
investigator, at screening.
o History of sustained and clinically significant supraventricular
arrhythmias (e. g. associated with hemodynamic compromise)
within 6 months of screening.
o Chronic heart failure New York Heart Association Class III or IV.
o Known presence of aortic aneurysm > 5 cm.
o Uncontrolled diabetes as defined by a random fasting glucose level
of 13 mmol/L or 240 mg/dL or a HbA1c greater than 9% as measured at screening. Diabetes should be treated as appropriate
during the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To evaluate following:
• Number of patients reported with any adverse events, serious adverse events and death [ Time Frame: 32 weeks]
• Change from baseline in maximum walking distance (MWD) as assessed by 6MWT [Time Frame: Base-line, 16 weeks] |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
•PK parameters will be determined, including: AUCinf, AUClast, AUC0-t, AUC0tau, Cmax and Tmax [Time Frame: 1 hour pre-dose and 1 hour, 2 hour, 4 hour post-dose on Day 1; 0 hour pre-dose on Day 29 and Day 57; 0 hour pre-dose and 1 hour, 2 hour, 4 hour post-dose on Day 85]
• Change from baseline in pain-free walking distance as assessed by 6MWT [Time Frame: Base-line, 16 weeks] |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Korea, Republic of |
Romania |
Taiwan |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 15 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 16 |
E.8.9.2 | In all countries concerned by the trial days | 0 |